Major readouts from the annual diabetes conference
-
By
-
Theresa Gaffney
-
June 8, 2026
-
Clinical Scorecard: Key Insights from the Annual Diabetes Association Conference
At a Glance
| Category | Detail |
|---|
| Condition | |
| Key Mechanisms | |
| Target Population | |
| Care Setting | American Diabetes Association Annual Conference |
Key Highlights
- Safety and tolerability data on Eli Lilly’s next-gen obesity drug presented, including specific outcomes.
- Detailed data from a mid-stage study on Pfizer's obesity drug discussed, highlighting key results.
- New data on Boehringer Ingelheim’s obesity drug shared, with emphasis on efficacy.
Guideline-Based Recommendations
Diagnosis
- Consider including diagnostic criteria for diabetes and obesity.
Management
- Outline management strategies discussed at the conference.
Monitoring & Follow-up
- Include monitoring recommendations based on new findings.
Risks
- Discuss potential risks associated with new treatments.
Patient & Prescribing Data
Patients with diabetes and obesity
Focus on GLP-1 receptor agonists and emerging obesity treatments.
Clinical Best Practices
- Summarize best practices for managing diabetes and obesity based on conference insights.
Related Resources & Content
